PMID- 35988043 OWN - NLM STAT- MEDLINE DCOM- 20221129 LR - 20230415 IS - 1365-2230 (Electronic) IS - 0307-6938 (Print) IS - 0307-6938 (Linking) VI - 47 IP - 12 DP - 2022 Dec TI - Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis. PG - 2234-2241 LID - 10.1111/ced.15384 [doi] AB - BACKGROUND: Psoriasis is a chronic inflammatory skin disease associated with several important medical comorbidities. There are scant data available on the comorbidities of patients with psoriasis in South America. AIM: To examine the comorbidity profile of adult patients with psoriasis in Chile and its association with severity of psoriasis. METHODS: This was a multicentre, cross-sectional study involving 16 hospitals and clinics in Chile, which used a 48-item questionnaire to study clinician- and patient-reported outcomes and comorbidities. Inferential analyses were performed by psoriasis severity, using Fisher exact test, Student t-test and multivariable logistic regression. RESULTS: In total, 598 adult patients with psoriasis were included (51.1% male; mean age 49.2 +/- 15.1 years); 48.5% mild and 51.4% moderate to severe; Psoriasis Area and Severity Index 11.6 +/- 11.5; body surface area 14.7 +/- 18.2%. Plaque psoriasis was the most common phenotype (90.2%), followed by guttate (13.4%). Psoriatic arthritis occurred in 27.3% of patients. Comorbidities were reported in 60.2% of all patients with psoriasis. Frequent concomitant diseases were obesity (25.3%), hypertension (24.3%), Type 2 diabetes mellitus (T2DM) (18.7%), dyslipidaemia (17.4%), metabolic syndrome (16.7%) and depression (14.4%). After adjustment, significant associations were found between moderate to severe psoriasis and obesity, T2DM and nonalcoholic fatty liver disease (NAFLD) compared with mild psoriasis. CONCLUSIONS: We report a large study of comorbidities, including depression, dyslipidaemia, T2DM and NAFLD, in people with psoriasis in Chile. The prevalence of comorbidities with psoriasis in Chile appears similar to that found in Western countries, and emphasizes the importance of assessing patients with psoriasis for risk factors for and presence of, comorbid disease in a multidisciplinary setting. CI - (c) 2022 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. FAU - Valenzuela, Fernando AU - Valenzuela F AUID- ORCID: 0000-0003-1032-9347 AD - Department of Dermatology, University of Chile, Santiago, Chile. AD - Centro Internacional de Estudios Clinicos, Probity Medical Research, Santiago, Chile. FAU - De La Cruz, Claudia AU - De La Cruz C AD - Clinica Dermacross, Santiago, Chile. FAU - Lecaros, Cristobal AU - Lecaros C AUID- ORCID: 0000-0002-8509-1188 AD - Department of Dermatology, Clinica Alemana, Universidad del Desarrollo, Santiago, Chile. FAU - Fernandez, Javier AU - Fernandez J AUID- ORCID: 0000-0002-7110-3600 AD - Centro Internacional de Estudios Clinicos, Probity Medical Research, Santiago, Chile. FAU - Hevia, Gonzalo AU - Hevia G AD - Department of Dermatology, Clinica Alemana, Universidad del Desarrollo, Santiago, Chile. FAU - Maul, Lara Valeska AU - Maul LV AUID- ORCID: 0000-0001-9202-0073 AD - Department of Dermatology, University Hospital Basel, Basel, Switzerland. FAU - Thyssen, Jacob P AU - Thyssen JP AD - Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark. AD - University of Copenhagen, Copenhagen, Denmark. FAU - Vera-Kellet, Cristian AU - Vera-Kellet C AUID- ORCID: 0000-0001-8697-9245 AD - Department of Dermatology, Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile. FAU - Egeberg, Alexander AU - Egeberg A AUID- ORCID: 0000-0001-8257-1816 AD - Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark. AD - University of Copenhagen, Copenhagen, Denmark. FAU - Armijo, Daniela AU - Armijo D AD - Clinica Dermacross, Santiago, Chile. FAU - Pizarro, Cristian AU - Pizarro C AD - Department of Dermatology, Universidad Austral Campus Osorno, Osorno, Chile. FAU - Riveros, Tatiana AU - Riveros T AD - Department of Dermatology, Clinica Alemana, Universidad del Desarrollo, Santiago, Chile. FAU - Correa, Hernan AU - Correa H AD - Centro Dermatologico DERMAMED, Santiago, Chile. AD - Department of Dermatology, Hospital Dr Sotero del Rio, Santiago, Chile. FAU - Guglielmetti, Antonio AU - Guglielmetti A AD - Department of Dermatology, Universidad de Valparaiso, Valparaiso, Chile. FAU - Didaskalu, Johannes A AU - Didaskalu JA AD - Faculty of Medicine, University of Zurich, Zurich, Switzerland. FAU - Wu, Jashin J AU - Wu JJ AD - Department of Dermatology, University of Miami Miller School of Medicine, Miami, FL, USA. FAU - Griffiths, Christopher E M AU - Griffiths CEM AUID- ORCID: 0000-0001-5371-4427 AD - Dermatology Centre, Salford Royal Hospital, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, UK. AD - School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. FAU - Romiti, Ricardo AU - Romiti R AD - Department of Dermatology, University of Sao Paulo, School of Medicine, Sao Paulo, Brazil. FAU - Maul, Julia-Tatjana AU - Maul JT AUID- ORCID: 0000-0002-9914-1545 AD - Faculty of Medicine, University of Zurich, Zurich, Switzerland. AD - Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. LA - eng PT - Journal Article DEP - 20221028 PL - England TA - Clin Exp Dermatol JT - Clinical and experimental dermatology JID - 7606847 SB - IM MH - Male MH - Female MH - Humans MH - *Non-alcoholic Fatty Liver Disease/epidemiology MH - Chile/epidemiology MH - *Diabetes Mellitus, Type 2/epidemiology MH - Cross-Sectional Studies MH - *Psoriasis/epidemiology MH - Comorbidity MH - Obesity/epidemiology MH - *Dyslipidemias MH - Delivery of Health Care PMC - PMC10092698 COIS- FV has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Amgen, Eli Lilly, LEO Pharma, Janssen-Cilag, Novartis, Pfizer and Sanofi. CDLC has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Amgen, Boehringer-Ingelheim, Bristol Myers Squibb, Coherus, Eli Lilly, Genentech, Janssen-Cilag, Novartis, Pfizer, Sanofi and UCB. CL has participated in clinical trials sponsored by Sanofi, Pfizer and Novartis. JF has participated in clinical trials sponsored by Pfizer and Novartis. DA has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Janssen-Cilag and LEO Pharma. CP has participated in clinical trials sponsored by SANOFI Genzyme and Novartis. HC has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by Serono, Novartis and Galderma. AG has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Janssen-Cilag, Novartis and Pfizer. CEMG has received honoraria and/or research funding from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Janssen-Cilag, LEO Pharma, Novartis, Pfizer and UCB. RR has served as a scientific consultant, speaker or clinical study investigator for AbbVie, Boehringer Ingelheim, Galderma, Janssen-Cilag, Eli-Lilly, Leo-Pharma, Novartis, Pfizer, TEVA and UCB. JTM has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, BMS, Celgene, Eli Lilly, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi and UCB. LVM has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by Almirall, Amgen, BMS, Celgene, Eli Lilly, MSD, Novartis, Pierre Fabre, Roche and Sanofi. JJW is or has been an investigator, consultant or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, DermTech, Dr Reddy's Laboratories, Eli Lilly, EPI Health, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Pfizer, Regeneron, Samsung Bioepis, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB and Zerigo Health. JPT is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi-Genzyme; a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi-Genzyme; and received research grants from Pfizer, Regeneron and Sanofi-Genzyme. AE has received research funding from Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation; and has received honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd. Galapagos NV, Sun Pharmaceuticals, Samsung Bioepis Co. Ltd. Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb and Janssen Pharmaceuticals. The remaining authors declare that they have no conflict of interest. EDAT- 2022/08/22 06:00 MHDA- 2022/11/30 06:00 PMCR- 2023/04/12 CRDT- 2022/08/21 05:52 PHST- 2022/08/19 00:00 [accepted] PHST- 2022/08/22 06:00 [pubmed] PHST- 2022/11/30 06:00 [medline] PHST- 2022/08/21 05:52 [entrez] PHST- 2023/04/12 00:00 [pmc-release] AID - CED15384 [pii] AID - 10.1111/ced.15384 [doi] PST - ppublish SO - Clin Exp Dermatol. 2022 Dec;47(12):2234-2241. doi: 10.1111/ced.15384. Epub 2022 Oct 28.